131 related articles for article (PubMed ID: 38626769)
1. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum.
Ingels J; De Cock L; Stevens D; Mayer RL; Théry F; Sanchez GS; Vermijlen D; Weening K; De Smet S; Lootens N; Brusseel M; Verstraete T; Buyle J; Van Houtte E; Devreker P; Heyns K; De Munter S; Van Lint S; Goetgeluk G; Bonte S; Billiet L; Pille M; Jansen H; Pascal E; Deseins L; Vantomme L; Verdonckt M; Roelandt R; Eekhout T; Vandamme N; Leclercq G; Taghon T; Kerre T; Vanommeslaeghe F; Dhondt A; Ferdinande L; Van Dorpe J; Desender L; De Ryck F; Vermassen F; Surmont V; Impens F; Menten B; Vermaelen K; Vandekerckhove B
Cell Rep Med; 2024 May; 5(5):101516. PubMed ID: 38626769
[TBL] [Abstract][Full Text] [Related]
2. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW
Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.
Ge C; Li R; Song H; Geng T; Yang J; Tan Q; Song L; Wang Y; Xue Y; Li Z; Dong S; Zhang Z; Zhang N; Guo J; Hua L; Chen S; Song X
BMC Cancer; 2017 Dec; 17(1):884. PubMed ID: 29268708
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
Li F; Deng L; Jackson KR; Talukder AH; Katailiha AS; Bradley SD; Zou Q; Chen C; Huo C; Chiu Y; Stair M; Feng W; Bagaev A; Kotlov N; Svekolkin V; Ataullakhanov R; Miheecheva N; Frenkel F; Wang Y; Zhang M; Hawke D; Han L; Zhou S; Zhang Y; Wang Z; Decker WK; Sonnemann HM; Roszik J; Forget MA; Davies MA; Bernatchez C; Yee C; Bassett R; Hwu P; Du X; Lizee G
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244308
[TBL] [Abstract][Full Text] [Related]
7. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
8. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
Um SJ; Choi YJ; Shin HJ; Son CH; Park YS; Roh MS; Kim YS; Kim YD; Lee SK; Jung MH; Lee MK; Son C; Choi PJ; Chung J; Kang CD; Lee EY
Lung Cancer; 2010 Nov; 70(2):188-94. PubMed ID: 20223553
[TBL] [Abstract][Full Text] [Related]
10. [About the impact of the dendritic cell autovaccine on the results of treatment of non-small-cell lung cancer patients].
Sovenko VM; Khranovskaia NN; Ganul AV; Ganul VL; Grinevich IuA; Orel VÉ; Skachkova OV; Svergun NN; Bororov LV; Borisiuk BO; Kobzev OI; Shevchenko AI; Semivolos AV; Kondratskiĭ IuN
Lik Sprava; 2013 Sep; (6):68-72. PubMed ID: 25510092
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
12. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
13. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
[TBL] [Abstract][Full Text] [Related]
14. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
15. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
Ding Z; Li Q; Zhang R; Xie L; Shu Y; Gao S; Wang P; Su X; Qin Y; Wang Y; Fang J; Zhu Z; Xia X; Wei G; Wang H; Qian H; Guo X; Gao Z; Wang Y; Wei Y; Xu Q; Xu H; Yang L
Signal Transduct Target Ther; 2021 Jan; 6(1):26. PubMed ID: 33473101
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
17. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.
Perroud MW; Honma HN; Barbeiro AS; Gilli SC; Almeida MT; Vassallo J; Saad ST; Zambon L
J Exp Clin Cancer Res; 2011 Jun; 30(1):65. PubMed ID: 21682877
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
19. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
20. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
